Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend (12mg)

Description

Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Peptide Blend

Modified GRF 1-29 is a synthetic peptide with 29 amino acids. As an analog of the naturally occurring growth hormone-releasing hormone (GHRH), the structure is slightly altered with the intention of providing more stable groups to replace the original four amino acids – hence, it is called Modified GRF 1-29 peptide (Mod GRF 1-29).⁽¹⁾ Ipamorelin is a synthetic pentapeptide, falling under the growth hormone secretagogues (GHSR) agonist category. Fragment 176-191, as the name implies, is a small ‘fragment’ of the growth hormone (hGH), also referred to as the “fat-burning peptide” for its potential in that area.⁽²⁾ Fragment 176-191 peptide, composed of 15 amino acids 177 to 191 found in hGH, is also known as AOD 9604.⁽³⁾

Chemical Makeup^{(1) (3) (4)}

Molecular formula:
Modified GRF 1-29: C₁₅₂H₂₅₂N₄₄O₄₂
Ipamorelin: C₃₈H₄₉N₉O₅
Fragment 176-191: C₇₈H₁₂₅N₂₃O₂₃S₂

Molecular weight:
Modified GRF 1-29: 3367.9 g/mol
Ipamorelin: 711.9 g/mol
Fragment 176-191: 1817.12 g/mol

Other known titles:
Modified GRF 1-29

• CJC 1295 Without DAC
• Mod GRF (1-29)

Ipamorelin

• Ipamorelin Acetate
• IPA

Fragment 176-191

• AOD 9604
• GH (hGH) lipolytic fragment
• Somatostatin (177-191), tyrosyl

Research and Clinical Studies

Fragment 176-191 & Modified GRF 1-29 & Ipamorelin Blend, and Lipolytic Action

In one study,⁽²⁾ obese experimental mice were subjected to the peptide for two consecutive weeks. After the completion of the study, it was noted that there appeared to be a significant reduction in the body weight of these mice, including a reduction of excess body lipids. These results were deemed correlated to the increased concentration of the lipolytic ß3-AR receptors, indicating the peptides may work via the beta-adrenergic pathway.  Further studies were conducted on the experimental mice with knocked-out lipolytic receptors. The peptide mice showed considerable weight loss, suggesting that the peptide does not depend on the lipolytic receptors to exert any action. Instead, it may produce possible the fat-burning action via energy expenditure and fat oxidation.  As per M Heffernan and his team, “this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the beta(3)-AR although both compounds increase beta(3)-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.”⁽²⁾

Fragment 176-191 & Modified GRF 1-29 & Ipamorelin Blend, and GSHs, GHRHs

One clinical study⁽⁵⁾ was conducted in test subjects presented with different concentrations of peptides and monitored for any physiological changes.  After completing this study, it was suggested that these peptides appeared to yield various bodily changes, including enhanced body growth, increased hunger, improved lean body mass, improved sleep cycle, and reduced bone turnover in obese subjects. These peptides were reported to “increase lean body mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, enhance muscle strength, and improve linear growth…”⁽⁵⁾

Fragment 176-191 & Modified GRF 1-29 & Ipamorelin Blend, and Fat Burning

In 2004, a clinical trial⁽⁶⁾ was launched, consisting of 300 obese test subjects. All these subjects were presented with the Fragment 176-191 peptide for 12 consecutive weeks. All subjects were divided into 6 groups – one group was presented with saline placebo, and the rest were given different peptide concentrations. After 12 weeks, when the subjects were examined, the group presented with the minor peptide concentration appeared to exhibit the highest reduction in their body weight (up to an average of 2.8 kilograms). Moreover, the trial also suggested that the peptide may have helped to improve these candidates’ cholesterol profiles and glucose tolerance levels.  As per Chris Belyea, “The evidence from the trial is that over 12 weeks AOD9604 induces competitive weight loss with accompanying health benefits at a low dose and has superior tolerability.”  ⁽⁶⁾

Fragment 176-191 & Modified GRF 1-29 & Ipamorelin Blend, and Regeneration

In one 2015 study,⁽⁷⁾ 32 experimental rabbits were enrolled and divided into four groups of eight. All four groups were presented with placebo, Fragment 176-191 peptide, hyaluronic acid, or a combination of the peptide and hyaluronic acid. This study was conducted for approximately 7 weeks. After the completion of the study, all rabbits were examined for cartilage damage. Among all groups, the rabbits presented with the peptide and hyaluronic acid combination appeared to exhibit minor cartilage degeneration. The report concluded that “Intra-articular AOD9604 [administration] using ultrasound guidance enhanced cartilage regeneration, and combined AOD9604 and HA [administration] were more effective than HA or AOD9604 [doses] alone in the collagenase-induced knee OA rabbit model.” ⁽⁷⁾

Fragment 176-191 & Modified GRF 1-29 & Ipamorelin Blend, and Sleep Cycle

Studies⁽⁸⁾ have indicated that the amount of growth hormones secreted may possibly affect the deep non-REM sleep cycle (NREMS) on a daily basis. Presenting the peptide blend of Fragment 176-191, Ipamorelin, and Modified GRF 1-29 peptides may not only help increase the secretion of growth hormones in the body but may also impact the sleep cycle.  According to the researchers, “Mutant and transgenic animals with a defect in GHRHergic activity display permanently reduced NREMS, which cannot be reversed by means of GH supplementation. GHRH contents and mRNA levels in the hypothalamus correlate with sleep-wake activity during the diurnal cycle and sleep deprivation and recovery sleep. Stimulation of NREMS by GHRH is a hypothalamic action. GABAergic neurons in the anterior hypothalamus/preoptic region are candidates for mediating promotion of NREMS by GHRH.”⁽⁸⁾

Fragment 176-191 & Modified GRF 1-29 & Ipamorelin peptide blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References

1. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC.
2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213. https://pubmed.ncbi.nlm.nih.gov/11713213/
3. National Center for Biotechnology Information (2023). PubChem Substance Record for SID 319360420, 386264-39-7, Source: ToxPlanet. https://pubchem.ncbi.nlm.nih.gov/substance/319360420
4. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin.  https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.
5. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
6. News, Medical and Life Sciences, Obesity drug codenamed AOD 9604 highly successful in trials, 16 December 2004, https://www.news-medical.net/news/2004/12/16/6878.aspx.
7. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694. https://pubmed.ncbi.nlm.nih.gov/26275694/
8. Obal F Jr, Krueger JM. GHRH and sleep. Sleep Med Rev. 2004 Oct;8(5):367-77. doi: 10.1016/j.smrv.2004.03.005. PMID: 15336237. https://pubmed.ncbi.nlm.nih.gov/15336237/

NOTE: These products are intended for laboratory research use only. Fragment 176-191 & Modified GRF 1-29 & Ipamorelin Blend for sale (12mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.